Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
McKesson
Johnson and Johnson
Daiichi Sankyo
Express Scripts
Accenture
US Department of Justice
Dow
Colorcon
Cipla

Generated: August 21, 2017

DrugPatentWatch Database Preview

Glimepiride; pioglitazone hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for glimepiride; pioglitazone hydrochloride and what is the scope of glimepiride; pioglitazone hydrochloride freedom to operate?

Glimepiride; pioglitazone hydrochloride
is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa and Sandoz, and is included in two NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Glimepiride; pioglitazone hydrochloride has one hundred and twenty-six patent family members in thirty-six countries.

There are fourteen drug master file entries for glimepiride; pioglitazone hydrochloride. Three suppliers are listed for this compound.

Summary for Generic Name: glimepiride; pioglitazone hydrochloride

Tradenames:2
Patents:3
Applicants:2
NDAs:2
Drug Master File Entries: see list14
Suppliers / Packagers: see list3
Clinical Trials: see list2,784
Drug Prices:see low prices
DailyMed Link:glimepiride; pioglitazone hydrochloride at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
DUETACT
glimepiride; pioglitazone hydrochloride
TABLET;ORAL021925-002Jul 28, 2006ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Takeda Pharms Usa
DUETACT
glimepiride; pioglitazone hydrochloride
TABLET;ORAL021925-002Jul 28, 2006ABRXYesNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
DUETACT
glimepiride; pioglitazone hydrochloride
TABLET;ORAL021925-001Jul 28, 2006ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Sandoz
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
glimepiride; pioglitazone hydrochloride
TABLET;ORAL201049-001Jan 4, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
DUETACT
glimepiride; pioglitazone hydrochloride
TABLET;ORAL021925-001Jul 28, 2006ABRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: glimepiride; pioglitazone hydrochloride

Non-Orange Book Patents for Generic Ingredient: glimepiride; pioglitazone hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,239,153 Pharmaceutical composition► Subscribe
6,156,773 Pharmaceutical composition► Subscribe
6,169,100 Pharmaceutical composition► Subscribe
6,133,295 Pharmaceutical composition► Subscribe
6,150,383 Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: glimepiride; pioglitazone hydrochloride

Country Document Number Estimated Expiration
Japan4809806► Subscribe
Hong Kong1041203► Subscribe
Ukraine91729► Subscribe
Australia2006328328► Subscribe
Cyprus2424► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/011United Kingdom► SubscribePRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU
2007 00001Denmark► Subscribe
C/GB07/009United Kingdom► SubscribeSPC/GB07/009: 20070126
298Luxembourg► Subscribe91298, EXPIRES: 20210620
0861666/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Harvard Business School
QuintilesIMS
Mallinckrodt
Citi
Healthtrust
McKinsey
Chinese Patent Office
Medtronic
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot